These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 33171747)

  • 1. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.
    Plaza-Díaz J; Solís-Urra P; Rodríguez-Rodríguez F; Olivares-Arancibia J; Navarro-Oliveros M; Abadía-Molina F; Álvarez-Mercado AI
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.
    Kobayashi T; Iwaki M; Nakajima A; Nogami A; Yoneda M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacts of gut microbiota alteration on age-related chronic liver diseases.
    Adhikary S; Esmeeta A; Dey A; Banerjee A; Saha B; Gopan P; Duttaroy AK; Pathak S
    Dig Liver Dis; 2024 Jan; 56(1):112-122. PubMed ID: 37407321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Li H; Shi J; Zhao L; Guan J; Liu F; Huo G; Li B
    J Agric Food Chem; 2021 Jan; 69(1):183-197. PubMed ID: 33353302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
    Chen YH; Wu WK; Wu MS
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal microbiota in liver disease.
    Haque TR; Barritt AS
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Microbiota: What Do We Know about It at Present?
    Derovs A; Laivacuma S; Krumina A
    Medicina (Kaunas); 2019 Aug; 55(8):. PubMed ID: 31405111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between the intestinal microbiome and liver diseases.
    Schnabl B; Brenner DA
    Gastroenterology; 2014 May; 146(6):1513-24. PubMed ID: 24440671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
    Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
    Chopyk DM; Grakoui A
    Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.